Kiora Pharmaceuticals to Webcast On-Demand Presentation at The H.C. Wainwright 27th Annual Global Investment Conference
Kiora Pharmaceuticals (NASDAQ:KPRX) announced that CFO Melissa Tosca will present the company's pipeline of therapies for inherited and inflammatory retinal diseases at the upcoming H.C. Wainwright 27th Annual Global Investment Conference.
The presentation is scheduled for September 5th, 2025, at 7:00 am EDT. Investors can access the presentation through the company's investor relations website, where it will remain available on-demand for 90 days.
Kiora Pharmaceuticals (NASDAQ:KPRX) ha annunciato che la CFO Melissa Tosca presenter脿 il portafoglio di terapie dell'azienda per le malattie retiniche ereditarie e infiammatorie al H.C. Wainwright 27th Annual Global Investment Conference.
La presentazione 猫 programmata per il 5 settembre 2025 alle 7:00 EDT. Gli investitori potranno visualizzare la presentazione sul sito investor relations dell'azienda, dove rimarr脿 disponibile on-demand per 90 giorni.
Kiora Pharmaceuticals (NASDAQ:KPRX) anunci贸 que la directora financiera Melissa Tosca presentar谩 la cartera de terapias de la compa帽铆a para enfermedades retinianas hereditarias e inflamatorias en la H.C. Wainwright 27th Annual Global Investment Conference.
La presentaci贸n est谩 programada para el 5 de septiembre de 2025 a las 7:00 EDT. Los inversores podr谩n acceder a la presentaci贸n a trav茅s del sitio web de relaciones con inversores de la compa帽铆a, donde permanecer谩 disponible bajo demanda durante 90 d铆as.
Kiora Pharmaceuticals (NASDAQ:KPRX)電� 斓滉碃鞛毂呾瀯鞛� 氅滊Μ靷� 韱犾姢旃搓皜 H.C. Wainwright 鞝�27須� 鞐半 旮�搿滊矊 韴瀽 旎嵓霟办姢鞐愳劀 鞙犾爠靹� 氚� 鞐检靹� 毵濍 歆堩櫂鞚� 鞙勴暅 須岇偓鞚� 旃橂 韺岇澊頂勲澕鞚胳潉 氚滍憸頃� 瓴冹澊霛缄碃 氚滍憸頄堨姷雼堧嫟.
氚滍憸 鞚检爼鞚� 2025雲� 9鞗� 5鞚� 鞓れ爠 7:00 EDT鞛呺媹雼�. 韴瀽鞛愲摛鞚� 須岇偓鞚� 韴瀽鞛� 甏�瓿� 鞗轨偓鞚错姼毳� 韱淀暣 氚滍憸毳� 鞁滌箔頃� 靾� 鞛堨溂氅�, 頃措嫻 鞛愲電� 90鞚� 霃欖晥 鞓敂毵摐搿� 鞝滉车霅╇媹雼�.
Kiora Pharmaceuticals (NASDAQ:KPRX) a annonc茅 que la directrice financi猫re Melissa Tosca pr茅sentera le portefeuille de th茅rapies de la soci茅t茅 pour les maladies r茅tiniennes h茅r茅ditaires et inflammatoires lors de la H.C. Wainwright 27th Annual Global Investment Conference.
La pr茅sentation aura lieu le 5 septembre 2025 脿 7h00 EDT. Les investisseurs pourront consulter la pr茅sentation via le site web des relations investisseurs de la soci茅t茅, o霉 elle restera disponible 脿 la demande pendant 90 jours.
Kiora Pharmaceuticals (NASDAQ:KPRX) gab bekannt, dass CFO Melissa Tosca die Pipeline des Unternehmens f眉r vererbbare und entz眉ndliche Netzhauterkrankungen auf der H.C. Wainwright 27th Annual Global Investment Conference vorstellen wird.
Die Pr盲sentation ist f眉r den 5. September 2025 um 7:00 Uhr EDT angesetzt. Anleger k枚nnen die Pr盲sentation 眉ber die Investor-Relations-Website des Unternehmens aufrufen, wo sie f眉r 90 Tage on-demand verf眉gbar sein wird.
- None.
- None.
Encinitas, California--(Newsfile Corp. - September 4, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that its Chief Financial Officer, Melissa Tosca, CPA, will showcase the Company's pipeline of therapies targeting inherited and inflammatory retinal diseases at the H.C. Wainwright 27th Annual Global Investment Conference.
Presentation Details
| Date: | Friday, September 5th, 2025 |
| Time: | 7:00 am Eastern Daylight Time |
| Link: |
The replay will be available on-demand for 90 days on Kiora's investor relations website.
About Kiora Pharmaceuticals
Kiora Pharmaceuticals is a clinical-stage biotechnology company developing advanced therapies for retinal disease. We target critical pathways underlying retinal diseases using innovative small molecules to slow, stop, or restore vision loss. KIO-301 is being developed for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of retinal inflammation. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH).
In addition to news releases and SEC filings, we expect to post information on our website, , and social media accounts that could be relevant to investors. We encourage investors to follow us on X and LinkedIn as well as to visit our website and/or subscribe to email alerts.
Contact:
[email protected]
To view the source version of this press release, please visit
FAQ
When is Kiora Pharmaceuticals (KPRX) presenting at the H.C. Wainwright Conference?
Who will present for Kiora Pharmaceuticals at the H.C. Wainwright Conference?
What topics will Kiora Pharmaceuticals (KPRX) cover at the H.C. Wainwright Conference?
How can investors access Kiora Pharmaceuticals' H.C. Wainwright Conference presentation?
